Vous avez cherché: poor metabolizers (Anglais - Maltais)

cyp2c9 poor metabolizers
metabolizzaturi batuti ta’ cyp2c9

cyp2c9 poor metabolizers:
metabolizzaturi mhux daqstant tajbin ta ’ cyp2c9:

poor
ħażin -

poor boy
miskien

working poor
ħaddiema foqra

“poor quality”
“kwalità ħażina”

poor skin contact
kuntatt ħażin mal- ġilda

just 2 % were poor.
2 % biss kienu ta’ kwalità ħażina.

poor sleep quality
kwalità hażina ta’ irqad

the effects of desloratadine in poor metabolizers < 2 years of age have not been studied.
l-effetti ta’ desloratadine f’metabolizzaturi dgħajfin ta’ anqas minn sentejn ma kinux studjati.

poor quality eia reports
kwalità baxxa tar-rapporti tal-eia

the effects of aerius syrup in poor metabolizers < 2 years of age have not been studied.
l- effetti ta ’ desloratadine f’ metabolizzaturi dgħajfin ta ’ anqas minn sentejn ma kienux studjati.

known cyp2d6 poor metabolisers
metabolizzaturi dgħajfa magħrufa ta’ cyp2d6

poor governance constrains development.
governanza fqira trażżan l-iżvilupp.

however, clinical pharmacokinetic parameters are not significantly different between poor and extensive metabolizers of cyp2d6 substrates.
madankollu, il-parametri farmakokinetiċi kliniċi mhumiex differenti b’mod sinifikanti bejn metabolizzaturi batuti u estensivi tas-substrati ta’ cyp2d6.

in cyp2c9 poor metabolizers, co-administration of cyp3a4 inhibitors may increase systemic concentration of ospemifene to a larger extent.
f’metabolizzaturi batuti ta’ cyp2c9, l-għoti flimkien ta’ inibituri ta’ cyp3a4 jista’ jżid il- konċentrazzjoni sistemika ta’ ospemifene sa grad akbar.

in cyp2d6 poor metabolisers, concomitant use of potent inhibitors of cyp3a4 may result in higher plasma concentrations of aripiprazole compared to that in cyp2d6 extensive metabolizers.
fin-nies li jimmetabolizzaw is-cyp2d6 bil-mod, użu konkomitanti ta’inibituri potenti ta’ cyp3a4 jistgħu jirriżultaw f’konċentrazzjoni ogħla fil-plażma ta’ aripiprazole, meta mqabbel mal-livell fin-nies li jimmetabolizzaw is-cyp2d6 b’mod jgħaġġel.

patients who are known or suspected to be cyp2c9 poor metabolizers based on previous history/experience with other cyp2c9 substrates should be administered celecoxib with caution (see section 4.2).
il-pazjenti magħrufin jew issuspettati li mhumiex metabolizzaturi daqstant tajbin ta’ cyp2c9 fuq il- bażi tal-istorja/esperjenza preċedenti b’substrati oħra ta’ cyp2c9 għandhom jingħataw celecoxib b’kawtela (ara sezzjoni 4.2).

co-administration of senshio with strong/moderate cyp3a4 inhibitors should be avoided in patients who are known, or suspected to be cyp2c9 poor metabolizers based on genotyping or previous history/experience with other cyp2c9 substrates.
l-għoti ta’ senshio flimkien ma’ inibituri qawwija/moderati ta’ cyp3a4 għandu jiġi evitat f’pazjenti li huma magħrufa, jew issuspettati li huma metabolizzaturi dgħajfin ta’ cyp2c9, ibbażat fuq genotyping jew storja medika/esperjenza preċedenti b’substrati oħrajn ta’ cyp2c9.

cyp2c9 poor metabolizers: patients who are known or suspected to be cyp2c9 poor metabolizers based on genotyping or previous history/experience with other cyp2c9 substrates should be administered celecoxib with caution, as the risk of dose-dependent adverse effects is increased.
metabolizzaturi mhux daqstant tajbin ta’ cyp2c9: pazjenti magħrufa jew issuspettati li huma metabolizzaturi mhux daqstant tajbin ta’ cyp2c9 fuq il-bażi tal-ġenotip jew l-istorja/esperjenza preċedenti b’substrati oħra ta’ cyp2c9 għandhom jingħataw celecoxib b’kawtela, billi dawn għandhom riskju akbar ta’ effetti ħżiena dipendenti fuq id-doża.